ASS1
Argininosuccinate synthase
Also known as: ASS, ASSY_HUMAN, CTLN1
Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene
Protein identityUniProt · HPA
- UniProt accession
- P00966
- Gene
- ASS1
- Ensembl
- ENSG00000130707
- Chromosome
- 9
- Canonical length
- 412 aa
- Protein class
- Disease related genes, Enzymes, Human disease related genes, Metabolic proteins, Plasma proteins, Potential drug targets, Predicted intracellular proteins
- Subcellular location
- Nucleoplasm,Cytosol
- Quaternary structure
- Homotetramer
OverviewNCBI Gene
The protein encoded by this gene catalyzes the penultimate step of the arginine biosynthetic pathway. There are approximately 10 to 14 copies of this gene including the pseudogenes scattered across the human genome, among which the one located on chromosome 9 appears to be the only functional gene for argininosuccinate synthetase. Mutations in the chromosome 9 copy of this gene cause citrullinemia. Two transcript variants encoding the same protein have been found for this gene. [provided by RefSeq, Aug 2012]
Canonical amino-acid sequenceUniProt
412 residues, UniProt reviewed canonical sequence.
>P00966|ASS1
1 MSSKGSVVLA YSGGLDTSCI LVWLKEQGYD VIAYLANIGQ KEDFEEARKK ALKLGAKKVF
61 IEDVSREFVE EFIWPAIQSS ALYEDRYLLG TSLARPCIAR KQVEIAQREG AKYVSHGATG
121 KGNDQVRFEL SCYSLAPQIK VIAPWRMPEF YNRFKGRNDL MEYAKQHGIP IPVTPKNPWS
181 MDENLMHISY EAGILENPKN QAPPGLYTKT QDPAKAPNTP DILEIEFKKG VPVKVTNVKD
241 GTTHQTSLEL FMYLNEVAGK HGVGRIDIVE NRFIGMKSRG IYETPAGTIL YHAHLDIEAF
301 TMDREVRKIK QGLGLKFAEL VYTGFWHSPE CEFVRHCIAK SQERVEGKVQ VSVLKGQVYI
361 LGRESPLSLY NEELVSMNVQ GDYEPTDATG FININSLRLK EYHRLQSKVT AKLocalizationUniProt · AlphaFold · HPA
Whether an antibody against ASS1 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.
- Antibody reachability
- Intracellular
- Secreted
- No
- Transmembrane segments
- 0
- Mean surface accessibility (rSASA)
- 0.26
- Highest tissue expression
- 1,907 nTPM
Expression across tissuesHPA
Tissue
- liver: 1,907 nTPM
- kidney: 1,201 nTPM
- urinary bladder: 270 nTPM
- adipose tissue: 210 nTPM
- small intestine: 184 nTPM
- breast: 170 nTPM
Single-cell type
- hepatocytes: 1,157 nCPM
- enterocytes: 618 nCPM
- proximal tubule cells: 453 nCPM
- urothelial cells: 408 nCPM
- prostatic hillock cells: 399 nCPM
- prostatic club cells: 337 nCPM
Immune cell
- plasmacytoid DC: 1.5 nTPM
- myeloid DC: 0.1 nTPM
- basophil: 0 nTPM
- classical monocyte: 0 nTPM
- eosinophil: 0 nTPM
- gdT-cell: 0 nTPM
Brain region
- choroid plexus: 105 nTPM
- pons: 85 nTPM
- midbrain: 65 nTPM
- medulla oblongata: 60 nTPM
- hypothalamus: 56 nTPM
- cerebral cortex: 40 nTPM
DiseaseUniProt · ClinVar · IEDB · PubMed
Four sources answering four different questions about ASS1.
Disease | AllUniProt
Conditions ASS1 is implicated in, by any mechanism.
- Citrullinemia 1 (CTLN1) MIM:215700
Disease | GeneticClinVar
230 pathogenic / likely-pathogenic of 945 ClinVar records.
Conditions with pathogenic or likely-pathogenic variants.
- Citrullinemia type I
- Citrullinemia
- ASS1-related disorder
- Thyroid cancer, nonmedullary, 1
- See cases
Genetic constraint and essentialitygnomAD · DepMap
Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.
- gnomAD LOEUF (loss-of-function intolerance)
- 0.98
- gnomAD pLI
- 0
- gnomAD missense Z
- 0.76
- DepMap mean gene effect
- -0.22
- DepMap dependency class
- selective
Cancer expressionTCGA
Across TCGA tumor cohorts, this protein is over-expressed in roughly 4% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).
OntologyGO
Biological processes
- acute-phase response
- aspartate metabolic process
- cellular response to amine stimulus
- cellular response to amino acid stimulus
- cellular response to ammonium ion
- cellular response to cAMP
- cellular response to dexamethasone stimulus
- cellular response to glucagon stimulus
- cellular response to laminar fluid shear stress
- cellular response to lipopolysaccharide
- cellular response to oleic acid
- cellular response to tumor necrosis factor
- cellular response to type II interferon
- circadian rhythm
- citrulline metabolic process
- diaphragm development
- kidney development
- L-arginine biosynthetic process
- liver development
- midgut development
- negative regulation of leukocyte cell-cell adhesion
- positive regulation of nitric oxide biosynthetic process
- response to estradiol
- response to growth hormone
- response to mycotoxin
- response to nutrient
- response to xenobiotic stimulus
- response to zinc ion
- urea cycle
- argininosuccinate metabolic process
Molecular functions
- amino acid binding
- ATP binding
- identical protein binding
- RNA binding
- toxic substance binding
- argininosuccinate synthase activity
Cellular components
Protein domainsUniProt · Pfam · InterPro
- Rossmann-like alpha/beta/alpha sandwich fold
- Argininosuccinate synthase
- Argininosuccinate synthase, conserved site
- Argininosuccinate synthase, type 1 subfamily
- Argininosuccinate synthetase, catalytic/multimerisation domain body
- Arginosuccinate synthase-like, N-terminal domain
- Arginosuccinate synthase C-terminal domain
- Arginosuccinate synthase N-terminal HUP domain
- Arginosuccinate synthase C-terminal domain
KeywordsUniProt
InteractionsUniProt · HPA
Protein binding partners of ASS1 in the human serome: UniProt-annotated complex subunits plus reported interactors. Each links to its own Seroatlas record.
Antibody and autoantibody relevanceSeroatlas analysis
Seroatlas reads ASS1 as an antibody target. Whether an autoantibody or antibody against ASS1 could matter depends on whether native ASS1 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.
ASS1 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.
Annotation status
The present source text does not explicitly label ASS1 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.
Loading the interactive Seroatlas protein explorer...